Harrow Health, Inc. 8.625% Senior Notes due 2026 (HROWL) Stock Price, News & Analysis

Company Overview

Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) are unsecured, senior debt securities issued by Harrow Health Operating Company, LLC, a wholly owned subsidiary of Harrow Health, Inc. The notes carry a fixed interest rate of 8.625% per annum payable semi-annually and mature in July 2026. Proceeds from the issuance have been employed to fund strategic acquisitions, support ongoing operating needs and refinance existing indebtedness, in line with the company’s efforts to expand its footprint in the eye care market.

Harrow Health, Inc., the parent of the note issuer, operates as a multi‐brand eye health company focused on the development, manufacturing and commercialization of prescription ophthalmic products. Its portfolio includes both proprietary and partnered therapies that address conditions such as dry eye, intraocular pressure and ocular inflammation. The company’s business model combines in‐house research and development with compounding pharmacy services and strategic collaborations to accelerate product launches and enhance patient access.

The company’s operations are primarily concentrated in the United States, where it leverages a network of specialty pharmacies, distribution partners and telehealth platforms to extend its reach into diverse care settings. Since its founding—as ImprimisRx in 2008 and rebranded to Harrow Health in 2021—it has executed multiple acquisitions to broaden its ophthalmic pipeline and service capabilities. Leadership is anchored by CEO Scott Richards, who brought extensive experience in specialty pharmaceuticals and public company management to the organization.

The 8.625% Senior Notes due 2026 are listed on the Nasdaq exchange under the symbol HROWL. As senior unsecured obligations, they rank equally with Harrow Health Operating Company’s other senior unsecured debt and are effectively subordinated to any future secured indebtedness. Investors in these notes seek exposure to Harrow Health’s growth trajectory in the specialized eye care sector while earning a fixed income return through mid-2026.

Key Stats

• Today's Range: $25.17 to $25.61
• 50-Day Range: $25.17 to $25.72
• 52-Week Range: $25.05 to $25.72
• Volume: N/A
• Average Volume: 10,691 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:HROWL
• CIK: 1360214
• Web: harrowinc.com
• Phone: N/A
• Fax: N/A
• Employees: 22
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A